Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

NEW YORK, Dec. 17, 2010 /PRNewswire-FirstCall/ -- A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.  Over 60% of neurologists in ITG's study cited safety concerns and monitoring as limiting their use of the drug, but most indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.  Early switching data from ITG's proprietary panel of neurologists indicates that BIIB's Avonex may be the biggest loser of all, as nearly one-third of switches to Gilenya thus far have been from Avonex.

The study titled Event Pulse: Launch of Gilenya shows that Gilenya has been detailed heavily to neurologists since its launch.  Neurologists in the study reported more frequent details on Gilenya in November than any of the other MS therapies.  Study findings reveal that Novartis reps seem to be promoting the drug's unique oral formulation and its efficacy compared to market leaders, especially Biogen Idec's Avonex. Still, results from the study show that Novartis has not been able to completely allay neurologists' concerns about Gilenya's safety. Until resolved, Gilenya will likely be prescribed primarily for patients who have discontinued or have had an inadequate response to other MS therapie
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... RALEIGH, N.C. and ,S-HERTOGENBOSCH, the ... Europe ( http://www.healthlinkeurope.com ) has expanded its North American ... 100% medical facility, providing warehousing, fulfillment and order to ... North America , utilizing our global ERP platform. ... since 1994 serving our customers in Europe ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
(Date:9/2/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes Novian Health, Inc. with the ... Technology Innovation Leadership. Novian Health has greatly improved ... with its proprietary technology, Novilase ® Laser ... and easy-to-control ultrasound-guided thermo ablation device that performs ...
Breaking Medicine Technology:HealthLink Europe opens North American medical warehouse operation 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... 15 GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an ... and provided an,operational update for the quarter ended September ... September 30, 2007 The Company recorded a net ... 2007, compared to $283,434 for the same period in ...
... BRISBANE, Calif., Nov. 15 BiPar,Sciences, Inc., a ... announced it has initiated a Phase 2 study ... triple-negative breast,cancer that do not express the estrogen, ... the Phase 2 trial in this indication-which,represents a ...
Cached Medicine Technology:GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 6GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 7GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 8GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 9GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 10BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
(Date:9/2/2014)... with less intensive (and expensive) practice patterns appear to ... patients unnecessary and excessive medical care, according to a ... "Growing concern about the costs and harms of medical ... avoid the provision of unnecessary care," said lead author ... Dartmouth Institute for Health Policy & Clinical Practice. ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Evolve ... within the primary and urgent care arena, is ... opening coincides with a health fair the clinic ... incorporating technology to assist patients in achieving high ... Medical Clinics’ pricing structure is a groundbreaking change ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
Breaking Medicine News(10 mins):Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2
... But researcher stresses risk is still low , , MONDAY, Jan. ... the risk of developing brain cancer at a young age ... people with malignant brain tumors and 238 people with no ... most common type of brain cancer. Patients survive an average ...
... heart disease to rest , , MONDAY, Jan. 26 (HealthDay News) ... in vegetable oils, nuts and seeds possibly being bad for ... American Heart Association claims. , "There has been a lot ... might be bad," said William S. Harris, the nutritionist heading ...
... of American Physicians, Inc. Chief Executive Officer James L. ... Spirit of Life(R) Award, City of Hope,s ... celebrating Mr. Weidner and his award will be held ... Saturday, November 14. Spirit of Life(R) Award honorees ...
... Buy is Exclusive Retail Partner WARREN, N.J., Jan. ... VM ) announced today that it is joining ... of the LG Pink Flare limited edition handset, ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090126/NY62794 ) , (Logo: ...
... Nephros, Inc. (Pink Sheets: NEPH), a medical device company ... control, and water purification, today announced that its common ... the symbol "NEPH." The Company also announced that ... the NYSE Alternext US LLC (formerly, the American Stock ...
... people tend to overestimate the dangers, study finds, , , ... the minds of U.S. minorities and the disabled more ... , Ethnic minorities, as well as the disabled and ... changes based on terrorism fears, such as avoiding certain ...
Cached Medicine News:Health News:Omega-6 Fatty Acids Can Be Good for You 2Health News:Omega-6 Fatty Acids Can Be Good for You 3Health News:James L. Weidner Named 2009 Spirit of Life(R) Award Recipient by City of Hope 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 3Health News:Nephros Common Stock Now Quoted in Pink Sheets 2Health News:Nephros Common Stock Now Quoted in Pink Sheets 3Health News:Terror Fears Tougher on Minorities, Disabled 2Health News:Terror Fears Tougher on Minorities, Disabled 3
... 400 System is an automated multiplexing platform ... SNP detection, pathogen sequence detection and pharmacogenetics ... be applied to an open and flexible ... be reused until all tests sites have ...
... venous pressure monitoring, blood sampling, and ... polyurethane PICC line sets offer:, , ... Micropuncture Introducer Needle, Biocompatible Polyurethane ... to patient specific anatomy. Remove catheter ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Medicine Products: